STAT News

STAT+: Lilly says ‘triple-G’ drug beat Novo’s Ozempic in diabetes study

Data add to expectations that the drug will be one of Lilly’s greatest growth drivers.

By STAT News

1 min read
STAT+: Lilly says ‘triple-G’ drug beat Novo’s Ozempic in diabetes study
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights